• Teva Migraine Drug Wins FDA Approval

    10 days ago - By Fortune

    Teva Pharmaceutical Industries Ltd. won U.S. regulatory approval to sell a new treatment for migraines, a key part of the company's turnaround strategy. The stock surged in after-hours trading.
    The U.S. Food and Drug Administration approved Ajovy, an injection administered every few months to relieve migraines in adults, the Israeli drugmaker said in a statement late Friday. More than 36 million people in the U.S. suffer from these debilitating episodes, and the medicine could generate around $500 million of sales by 2022, according to analyst estimates compiled by Bloomberg.
    Ajovy's...
    Read more ...